Clinical Study Concerning Efgartigimod for the Treatment of CIDP Patients Enrolled in Neuroimmunological Disorders Registry

Clinical Study Concerning Efgartigimod for the Treatment of CIDP Patients Enrolled in Neuroimmunological Disorders Registry - Clinical Study Concerning Efgartigimod for the Treatment of CIDP Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056401

Enrollment

100

Registered

2025-04-01

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroimmune Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) CIDP patients* registered in the Neuroimmunological Disease Registry (as described in the study protocol [RADDAR-J[79]]) who are scheduled to begin Efgartigimod treatment *patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) based on the 2024 Clinical Practice Guidelines for CIDP and Multifocal Motor Neuropathy (MMN) 2) Patients who have provided written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
The course of clinical endpoints mainly used for each neuroimmune disease.	—

Secondary

Measure	Time frame
1. EQ-5D-5L 2. Treatment response 3. Adverse event	—

Countries

Japan

Contacts

Public ContactShigeki Omori

General Incorporated Association kizuna Secretariat

oomori-s@kizunaai.org0432397670

Outcome results